G Bali1, S Kárpáti2, M Sárdy2, V Brodszky3, B Hidvégi2, F Rencz3,4. 1. Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Mária u. 41., Budapest, 1085, Hungary. bali.gabor@med.semmelweis-univ.hu. 2. Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Mária u. 41., Budapest, 1085, Hungary. 3. Department of Health Economics, Corvinus University Budapest, Fővám tér 8., Budapest, 1093, Hungary. 4. Premium Postdoctoral Research Programme, Hungarian Academy of Sciences, Nádor u. 7., Budapest, 1051, Hungary.
Abstract
BACKGROUND: Morphea can lead to considerable cosmetic or functional impairment; nevertheless, health-related quality of life (HRQoL) is rarely documented in adult morphea patients. OBJECTIVE: To investigate the impact of morphea on HRQoL and to identify determinants of impaired HRQoL. METHODS: A cross-sectional study has been carried out among adult morphea patients. HRQoL was evaluated by the Dermatology Life Quality Index (DLQI). The modified Localised Scleroderma Skin Severity Index (mLoSSI) and the Localised Scleroderma Damage Index (LoSDI) were applied to evaluate disease activity and damage, respectively. Physician Global Assessment of Activity and Damage (PGA-A, PGA-D) were also completed. Determinants of HRQoL were analysed by multiple regression. RESULTS: A total of 101 patients (84% females) entered the study, with a mean age of 56.8 ± 14.8 years. Median mLoSSI, LoSDI, PGA-A and PGA-D scores were 8, 5, 9 and 9 points, respectively. Patients with generalised localised (51%) and plaque-type morphea (45%) had median total DLQI scores of 4 and 1, respectively. Embarrassment (53%), itchy or painful skin (46%), and clothing issues (43%) were the most commonly reported problems in the DLQI. Female gender, generalised morphea, higher disease activity (PGA-A score) and involvement of hands and/or feet were significant predictors of impaired HRQoL (p < 0.05). CONCLUSION: This study represents the largest sample of adult morphea patients surveyed about their HRQoL in Europe. The frequent occurrence of embarrassment warrants an increased attention to improve patients' mental health. Care must be taken in case of involvement of functionally sensitive areas, as these cases might require more intensive treatment.
BACKGROUND: Morphea can lead to considerable cosmetic or functional impairment; nevertheless, health-related quality of life (HRQoL) is rarely documented in adult morphea patients. OBJECTIVE: To investigate the impact of morphea on HRQoL and to identify determinants of impaired HRQoL. METHODS: A cross-sectional study has been carried out among adult morphea patients. HRQoL was evaluated by the Dermatology Life Quality Index (DLQI). The modified Localised Scleroderma Skin Severity Index (mLoSSI) and the Localised Scleroderma Damage Index (LoSDI) were applied to evaluate disease activity and damage, respectively. Physician Global Assessment of Activity and Damage (PGA-A, PGA-D) were also completed. Determinants of HRQoL were analysed by multiple regression. RESULTS: A total of 101 patients (84% females) entered the study, with a mean age of 56.8 ± 14.8 years. Median mLoSSI, LoSDI, PGA-A and PGA-D scores were 8, 5, 9 and 9 points, respectively. Patients with generalised localised (51%) and plaque-type morphea (45%) had median total DLQI scores of 4 and 1, respectively. Embarrassment (53%), itchy or painful skin (46%), and clothing issues (43%) were the most commonly reported problems in the DLQI. Female gender, generalised morphea, higher disease activity (PGA-A score) and involvement of hands and/or feet were significant predictors of impaired HRQoL (p < 0.05). CONCLUSION: This study represents the largest sample of adult morphea patients surveyed about their HRQoL in Europe. The frequent occurrence of embarrassment warrants an increased attention to improve patients' mental health. Care must be taken in case of involvement of functionally sensitive areas, as these cases might require more intensive treatment.
Entities:
Keywords:
DLQI; Health-related quality of life; LoSCAT; Localised scleroderma; Morphea
Authors: G Schmid-Ott; H W Kuensebeck; B Jaeger; T Werfel; K Frahm; J Ruitman; A Kapp; F Lamprecht Journal: Acta Derm Venereol Date: 1999-11 Impact factor: 4.437
Authors: R Knobler; P Moinzadeh; N Hunzelmann; A Kreuter; A Cozzio; L Mouthon; M Cutolo; F Rongioletti; C P Denton; L Rudnicka; L A Frasin; V Smith; A Gabrielli; E Aberer; M Bagot; G Bali; J Bouaziz; A Braae Olesen; I Foeldvari; C Frances; A Jalili; U Just; V Kähäri; S Kárpáti; K Kofoed; D Krasowska; M Olszewska; C Orteu; J Panelius; A Parodi; A Petit; P Quaglino; A Ranki; J M Sanchez Schmidt; J Seneschal; A Skrok; M Sticherling; C Sunderkötter; A Taieb; A Tanew; P Wolf; M Worm; N J Wutte; T Krieg Journal: J Eur Acad Dermatol Venereol Date: 2017-08-09 Impact factor: 6.166
Authors: Beata Szramka-Pawlak; Aleksandra Dańczak-Pazdrowska; Teresa Rzepa; Aleksandra Szewczyk; Anna Sadowska-Przytocka; Ryszard Zaba Journal: Appl Res Qual Life Date: 2013-11-10
Authors: Justyna Szczęch; Dominik Samotij; Kamila Jaworecka; Aleksandra Tobiasz; Adam Reich Journal: Biomed Res Int Date: 2020-03-13 Impact factor: 3.411
Authors: Anna Lis-Święty; Alina Skrzypek-Salamon; Irmina Ranosz-Janicka; Ligia Brzezińska-Wcisło Journal: Health Qual Life Outcomes Date: 2020-05-12 Impact factor: 3.186